CompletedNCT00167479
A Study of Risperidone Monotherapy in Bipolar Anxiety
Medication studyAges 18+United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Tampa and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- University of South Florida
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00167479
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder
Recruitment & locations
CompletedTampa · Cincinnati · Dallas
Questions about this study
Who is behind this study?
The study sponsor is University of South Florida, a university.
Did this study involve medication?
Yes. The study involved medication, including risperidone (Risperdal).
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolarity (BPD)
Abilify Therapy for Reducing Comorbid Substance Abuse